Selected article for: "control group and time ratio"
Author: de la Calle, Cristina; López-Medrano, Francisco; Pablos, José Luis; Lora-Tamayo, Jaime; Calle, Guillermo Maestro-de la; Sánchez-Fernández, Marcos; Fernández-Ruiz, Mario; Asín, María Asunción Pérez-Jacoiste; Caro-Teller, José Manuel; García-García, Rocío; Catalán, Mercedes; Martínez-López, Joaquín; Sevillano, Ángel; Origüen, Julia; Ripoll, Mar; Juan, Rafael San; Lalueza, Antonio; de Miguel, Borja; Carretero, Octavio; Aguilar, Fernando; Gómez, Carlos; Paz-Artal, Estela; Bueno, Héctor; Lumbreras, Carlos; Aguado, José María
Title: Effectiveness of anakinra for tocilizumab-refractory severe COVID-19. A single centre retrospective comparative study
  • Cord-id: iv67hm9c
  • Document date: 2021_2_13
    • ID: iv67hm9c
    Snippet: Objetives A subgroup of patients with SARS-CoV-2 infection is considered to develop a cytokine release syndrome and have been treated with tocilizumab, but a significant percentage of patients evolve. Our objective was to determine the usefulness of anakinra as rescue treatment for patients with tocilizumab-refractory COVID-19 disease. Methods A prospective cohort of patients with COVID19 pneumonia who received anakinra as salvage therapy after failure of tocilizumab were compared (1:1) to selec
    Document: Objetives A subgroup of patients with SARS-CoV-2 infection is considered to develop a cytokine release syndrome and have been treated with tocilizumab, but a significant percentage of patients evolve. Our objective was to determine the usefulness of anakinra as rescue treatment for patients with tocilizumab-refractory COVID-19 disease. Methods A prospective cohort of patients with COVID19 pneumonia who received anakinra as salvage therapy after failure of tocilizumab were compared (1:1) to selected controls in a historical cohort of patients treated with tocilizumab. Cases and controls were matched by age, comorbidities, pulse oximetry oxygen saturation to fraction of inspired oxygen (SpO2/FiO2) ratio at baseline and time elapsed since the initiation of treatment with tocilizumab. The primary outcome was the improvement in clinical status measured by a six-point ordinal scale, from baseline to day 21. Results The study included 20 cases and 20 controls (mean age 65.3±12.8 years, 65% males). No differences were found in the clinical improvement rates at 7, 14 and 21 days of follow-up. In-hospital mortality rate for patients receiving anakinra was 55% vs. 45% in the control group (P =0.527). Conclusions Treatment with anakinra was not useful to improve the prognosis of patients with tocilizumab-refractory severe COVID-19.

    Search related documents:
    Co phrase search for related documents
    • activation macrophage hemophagocytic lymphohistiocytosis and acute respiratory syndrome sars: 1, 2, 3, 4
    • activation macrophage hemophagocytic lymphohistiocytosis and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activation macrophage hemophagocytic lymphohistiocytosis and macrophage hemophagocytic lymphohistiocytosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activation macrophage hemophagocytic lymphohistiocytosis syndrome and acute ards respiratory distress syndrome: 1
    • activation macrophage hemophagocytic lymphohistiocytosis syndrome and acute respiratory syndrome sars: 1, 2, 3
    • activation macrophage hemophagocytic lymphohistiocytosis syndrome and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activation macrophage hemophagocytic lymphohistiocytosis syndrome and macrophage hemophagocytic lymphohistiocytosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and additional effect: 1, 2
    • acute ards respiratory distress syndrome and local committee: 1
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute ards respiratory distress syndrome and macrophage hemophagocytic lymphohistiocytosis: 1
    • acute respiratory syndrome sars and additional effect: 1, 2, 3
    • acute respiratory syndrome sars and additional marker: 1
    • acute respiratory syndrome sars and local committee: 1, 2, 3
    • acute respiratory syndrome sars and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome sars and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome sars and macrophage hemophagocytic lymphohistiocytosis: 1, 2, 3, 4
    • additional effect and lung damage: 1